Natural history study of lung papillomatosis

This early-phase trial tests how well pembrolizumab plus lenvatinib can treat respiratory papillomas that have spread to the lungs. It may help people whose lung disease is caused by human papillomavirus (HPV).

This Phase 1 trial is testing a vaccine made from your own immune cells (dendritic cells) that may help your body fight the virus causing recurrent papillomas in your voice box. It is for people whose papillomas are caused by HPV type 6, who have had at least one recurrence in the past year.

This trial tests if people with recurrent respiratory papillomatosis (growths in the airway caused by HPV) can safely get more doses of the study drug Zopa and checks if the virus spreads after treatment. It may help people who have already tried Zopa or are considering it for the first time.

This study tests whether an extra dose of the Gardasil-9 vaccine can help reduce the number of surgeries needed for recurrent respiratory papillomatosis (RRP), a condition where non-cancerous growths recur in the airway. You may be eligible if you've had the vaccine before and still have frequent recurrences.

This study is creating a national group of patients with juvenile recurrent respiratory papillomatosis, a condition causing wart-like growths in the airway. It aims to learn more about the disease and improve care.

This trial tests combining two drugs, bevacizumab and PRGN-2012, to treat recurrent respiratory papillomatosis (RRP), a condition where non-cancerous growths come back in the airway. The goal is to see if the combination reduces the need for surgeries or other procedures.